| Literature DB >> 34991070 |
Robert J Motzer1, Eric Jonasch2, Neeraj Agarwal3, Ajjai Alva4, Michael Baine5, Kathryn Beckermann6, Maria I Carlo1, Toni K Choueiri7, Brian A Costello8, Ithaar H Derweesh9, Arpita Desai10, Yasser Ged11, Saby George12, John L Gore13, Naomi Haas14, Steven L Hancock15, Payal Kapur16, Christos Kyriakopoulos17, Elaine T Lam18, Primo N Lara19, Clayton Lau20, Bryan Lewis21, David C Madoff22, Brandon Manley23, M Dror Michaelson24, Amir Mortazavi25, Lakshminarayanan Nandagopal26, Elizabeth R Plimack27, Lee Ponsky28, Sundhar Ramalingam29, Brian Shuch30, Zachary L Smith31, Jeffrey Sosman32, Mary A Dwyer33, Lisa A Gurski33, Angela Motter33.
Abstract
The NCCN Guidelines for Kidney Cancer focus on the screening, diagnosis, staging, treatment, and management of renal cell carcinoma (RCC). Patients with relapsed or stage IV RCC typically undergo surgery and/or receive systemic therapy. Tumor histology and risk stratification of patients is important in therapy selection. The NCCN Guidelines for Kidney Cancer stratify treatment recommendations by histology; recommendations for first-line treatment of ccRCC are also stratified by risk group. To further guide management of advanced RCC, the NCCN Kidney Cancer Panel has categorized all systemic kidney cancer therapy regimens as "Preferred," "Other Recommended Regimens," or "Useful in Certain Circumstances." This categorization provides guidance on treatment selection by considering the efficacy, safety, evidence, and other factors that play a role in treatment selection. These factors include pre-existing comorbidities, nature of the disease, and in some cases consideration of access to agents. This article summarizes surgical and systemic therapy recommendations for patients with relapsed or stage IV RCC.Entities:
Mesh：
Year: 2022 PMID： 34991070 DOI： 10.6004/jnccn.2022.0001
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908